Reneo Pharmaceuticals is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with deficiencies in mitochondrial energy production. The company's goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness and wasting. The experienced team of drug development experts, who have collaborated in many successful programs, is dedicated and passionate about finding effective therapies for these complex rare diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/20/19 | $50,000,000 | Series A |
Lundbeckfonden Ventures New Enterprise Associates  Pappas Capital RiverVest Venture Partners | undisclosed |
